Physician profile
Marcus B Goodman
NPI 1407075880
$64,598.18
in general payments reported to CMS, 2019-2025
44 companies · $8,402 in 2025
The $8,402 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,737 · 2020: $2,864 · 2021: $4,209 · 2022: $11K · 2023: $18K · 2024: $16K · 2025: $8,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Food and Beverage: $14K · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,200.00 |
| Food and Beverage | $13,971.02 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $18,985.61 | 2022-2024 | Tapinarof, Vtama |
| Leo Pharma INC. | $12,139.75 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $5,848.02 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Arcutis Biotherapeutics, INC. | $4,519.05 | 2023-2025 | Zoryve |
| Abbvie INC. | $3,533.77 | 2019-2025 | |
| Janssen Biotech, INC. | $3,149.73 | 2019-2025 | Tremfya, Remicade, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,365.01 | 2019-2025 | Jublia, Siliq, Targretin |
| Pfizer INC. | $1,638.27 | 2019-2025 | |
| Journey Medical Corporation | $1,453.25 | 2019-2025 | |
| Genzyme Corporation | $1,317.58 | 2019-2025 | |
| Ucb, INC. | $943.22 | 2020-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $934.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $932.56 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $881.62 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Amgen INC. | $850.46 | 2019-2025 | Otezla, Otezla |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $685.43 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $627.30 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $552.76 | 2019-2025 | |
| Incyte Corporation | $514.37 | 2021-2025 | Opzelura |
| Almirall LLC | $409.24 | 2019-2024 | Klisyri, Seysara |
| E.R. Squibb & Sons, L.L.C. | $346.24 | 2022-2025 | Sotyktu |
| Organon LLC | $329.81 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $299.11 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $249.68 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Prugen, INC. Pharmaceuticals | $161.92 | 2019-2020 | |
| Biofrontera INC. | $131.33 | 2019-2022 | |
| Stemline Therapeutics INC. | $117.76 | 2019 | |
| Celgene Corporation | $92.11 | 2019 | |
| Dusa Pharmaceuticals, INC. | $86.47 | 2019 | |
| Botanix Sb INC | $71.35 | 2025 | Sofdra |
| Sensus Healthcare, INC. | $60.17 | 2021 | |
| Sanofi-Aventis U.S. LLC | $57.22 | 2020 | |
| Ani Pharmaceuticals, INC. | $49.40 | 2025 | Veregen, Oxistat |
| Encore Dermatology INC. | $48.09 | 2019 | |
| Mylan Pharmaceuticals INC. | $36.51 | 2019 | |
| Kerecis Limited | $34.84 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Surgiclose, Kerecis Omega3 Graftguide |
| Dermira, INC. | $33.52 | 2020-2021 | |
| Strata Skin Sciences, INC. | $29.53 | 2024 | Xtrac |
| Glenmark Therapeutics INC. | $17.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2023 | Spevigo |
| Aclaris Therapeutics, INC. | $13.50 | 2019 | |
| Sandoz INC. | $13.14 | 2019 | |
| Mission Pharmacal Company | $12.00 | 2020 | |
| Promius Pharma LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.